At a glance
Summary
Waters’ weekly advance keeps the Diagnostics & Research name in a constructive regime, with active trend, positive Market Dynamics and Relative Strength, while valuation distance and only moderate volume confirmation keep risk control central.
- Waters rose 7.8% for the week and is up 23.6% over 12 weeks, closing at $406.9, or 94.6% of its 52-week range.
- The stock is 17.4% above its weekly Trend Line at $346.6 and 21.2% above Sharemaestro Fair Value at $335.8.
- Volume reached 6.0M shares, equal to 1.3x the 13-week average and 1.4x the 52-week average, confirming participation but not at a decisive 1.5x-plus level.
- Healthcare breadth is supportive, with 54.0% of names in active weekly trends and 77.0% showing positive Market Dynamics, though Relative Strength breadth is softer at 44.0%.
- The Trend Signal is active for a third week, but activity pressure carries no fresh buy signal and the broader expectancy read is undecided at 51.04%.
Company analysis
The move in context
Price action stretches towards the high
Waters Corporation finished the week ended 7 August at $406.9, up 7.8%, leaving the analytical laboratory instruments and software group just 1.8% below its 52-week high of $414.1. The move adds to an 8.1% four-week gain and a 23.6% 12-week advance, putting the stock near the top of its annual range after a sustained recovery from the $278.5 low.
The strength is clear, but so is the distance now embedded in the chart. Waters is trading 17.4% above its weekly Trend Line of $346.6 and 21.2% above Sharemaestro Fair Value of $335.8. That premium signals demand, yet it also raises the sensitivity to any loss of momentum, especially with the stock already at the 94.6% range position.
Sector support is present, but industry comparison is mixed
The Healthcare sector provided a constructive backdrop, averaging a 2.5% weekly gain and a 12.7% 12-week gain across the peer set. Waters outpaced that sector return profile over one week and 12 weeks, ranking in the 62.5th percentile among 953 US Healthcare names by the supplied peer measure.
Within US Diagnostics & Research, the comparison is more nuanced. The industry averaged a 5.9% weekly gain, 6.0% over four weeks and 33.1% over 12 weeks. Waters beat the group over one and four weeks, but its 23.6% quarterly move trails the industry’s more speculative high-beta winners, including CareDx, Twist Bioscience and Exagen. Industry breadth is still constructive, with 55.6% of names in active weekly trends and 80.0% showing positive Market Dynamics, while Relative Strength breadth at 42.2% shows that durable peer outperformance is narrower.
Trend Signal stays active, with measured confirmation
Sharemaestro’s signal state is constructive but not one-sided. Waters has an active Trend Signal and a three-week active streak, with price comfortably above the Trend Line. Market Dynamics is positive at 0.89, and the relative strength reading has improved to 4.53, moving back into supportive territory after a negative reading in mid-July.
Volume helps the case but stops short of a clean acceleration signal. The latest 6.0M-share week was above the 13-week average of 4.6M and the 52-week average of 4.2M, giving volume ratios of 1.3x and 1.4x respectively. That is credible participation for a 7.8% rise, though it is less forceful than the 8.9M-share week that accompanied the 15.6% gain in May.
Risk is about altitude, not breakdown
The main risk is not a broken trend, but a high-range stock with a sizeable valuation gap and a history of two-way weekly movement. Thirteen-week volatility is 5.0%, close to the 52-week level of 5.2%, while the past year shows 29 positive weeks against 23 negative weeks. Average up weeks have delivered 4.3%, compared with an average loss of 3.6%, a modestly favourable skew but not a low-volatility profile.
The watch-next frame is straightforward: whether price can press through the $414.1 high with stronger participation, whether activity pressure continues to improve, and whether the Trend Line near $346.6 remains distant support rather than a magnet if momentum fades. A volume ratio above 1.5x on the next meaningful move would provide stronger evidence that institutional participation is broadening.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line54.0%
Positive Relative Strength44.0%
US Diagnostics & Research
45 tracked companiesAbove Trend Line55.6%
Positive Relative Strength42.2%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 3-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- 1 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/waters-fair-value-premium-volume-confirmation-august-2026/.
Follow new Sharemaestro research through the RSS feed or JSON feed.